Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/13/2008

- Annual Xyrem(R) Net Sales Increase 34 Percent

- Investor Day Scheduled for March 13, 2008

PALO ALTO, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the fourth quarter and full year ended December 31, 2007.

Total revenues for the quarter ended December 31, 2007 were $15.5 million, compared to $12.4 million for the quarter ended December 31, 2006. Total revenues for the year ended December 31, 2007 increased 46 percent to $65.3 million, compared to $44.9 million for the year ended December 31, 2006. Xyrem(R) (sodium oxybate oral solution) net sales for the quarter ended December 31, 2007 increased 38 percent to $11.1 million, compared with $8.1 million for the last quarter of 2006. Xyrem net sales for the year ended December 31, 2007 increased 34 percent to $39.0 million, compared with $29.0 million for the year ended December 31, 2006.

"We are very pleased with the momentum we achieved in 2007. Our focus in 2008 will be on execution, including the planned commercial launch of LUVOX(R) CR in the first quarter of 2008 after anticipated FDA approval," said Samuel R. Saks, M.D., Chief Executive Officer. "Our portfolio of development-stage product candidates is making steady progress, and we believe that our development efforts will lead to important new products for patients and caregivers."

Jazz Pharmaceuticals' net loss for the fourth quarter of 2007 was $60.0 million, compared to a net loss of $20.5 million for the fourth quarter of 2006. For the year ended December 31, 2007, the company's net loss was $138.8 million, compared to a net loss of $59.4 million for the year ended December 31, 2006. Net loss for th
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
6. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
9. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2009)...re-USNewswire/ -- Human Genome Sciences, Inc. (Nas...ave top-line results available on Monday, July 20,...linical trials of BENLYSTA(TM) (belimumab, formerl... (SLE). , , (Logo: http://www.newscom.com/...anagement will host a conference call to discuss t...
(Date:6/30/2009)...s modified chlorophyll from an alga so that it res...acteria. The team was then able to determine the s...t step to converting sunlight into energy using an...ng an article on their research findings in the on...ek starting 29 June. Leiden researcher Swapna Gana...
(Date:6/30/2009)...irstCall/ -- In connection with its proposed acqui...pany Concateno plc, announced on June 5 2009, Inve... been requested by the UK Takeover Panel to remind...of their dealing disclosure obligations under Rule...losure requirements of the UK Takeover Code , ,...
(Date:6/30/2009)...e-FirstCall/ -- Hospira, Inc. (NYSE: HSP ), a gl...ery company, today announced agreements with MedAs....V. equipment, and a renewal of its agreement for ...ts are effective as of June 1, 2009, for I.V. solu...n devices. These new agreements represent a first ...
Breaking Biology Technology:Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus 2First step to converting solar energy using 'artificial leaf' 2Inverness Medical Innovations - Concateno plc, Further Announcement Regarding UK Takeover Code Share Dealing Disclosure Requirements. 2Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement 2
...ys been to build a business from scratch and sell ...eam in the 1990s but we wanted to speed it up so t... in a year or two. , ,In a few rare cases, thats ...s. The battle cry from entrepreneurs then was exac... is a virtue shared by fools and jackasses. As so ...
...on Consulting , , WTN: What technologies are prope...an: High speed and wireless networks enable any ...s becoming a determinant for where seniors relocat...ons of technology do you see in Wisconsin and how ...s in the state? , , Ryan: An interesting applica...
...ns , a Wisconsin-based provider of integrated data... center in their recently built Wisconsin headquar...f a new 13,000-square-foot technology facility tha...ata center located in the company,s new headquarte... network services related to Norlight,s products a...
...oved by the federal Food and Drug Administration p...or ways to speed up the laborious drug development...m the start of target discoveryidentifying a certa...eto introduce a new drug to market. The sheer leng...es and the research firms that contract with them ...
Other Biology Technology:An Overnight Business Success Takes 20 Years 2An Overnight Business Success Takes 20 Years 3Hot Technology, Hot Jobs and Cool Communities 2Hot Technology, Hot Jobs and Cool Communities 3Researchers Push for Faster Drug Development 2Researchers Push for Faster Drug Development 3
(Date:7/2/2009)...earchers from the National Oceanography Centre, So... oceanographic knowledge to investigate the distri...b. The results, published this week in the Journ...ng force behind the speciation and radiation of a ...f millions of years of Earth,s history. , In de...
(Date:7/2/2009)...remerhaven, July 2nd 2009. A new measurement syste...t time on board of the research vessel Polarstern....hand, they spend the greater part of their life un... their body can be seen when they surface, and thi...nding water. Visual sightings by marine mammal obs...
(Date:7/2/2009)...i Smith, Ph.D., an assistant professor of patholog...as Health Science Center at Houston, has received ...hilia Foundation. , The award will support Smit... people with Hemophilia A, a bleeding disorder, wh...ophilia A affects about one in every 5,000 males b...
(Date:7/2/2009)...HAM, N.C. -- As flowering plants like giant trees ...the Cretaceous period, the ferns that had preceded...ct, they flourished. While modern tropical rain fo...ard, and experienced a flowering of their own spec...m -- diversification," said Duke University resear...
Breaking Biology News(10 mins):Evolution: Crabs go deep to avoid hot water 2All in sight 2UT scientist receives hemophilia research award 2Ferns took to the trees and thrived 2Traditional risk assessment tools do not accurately predict coronary heart disease 33210 1Gen Probe to Webcast Presentation at the 27th Annual J P Morgan Healthcare Conference 33207 1Gen Probe to Webcast Presentation at the 27th Annual J P Morgan Healthcare Conference 33207 2Brains of Bulimia Patients Wired Differently 33204 1Brains of Bulimia Patients Wired Differently 33204 2Brains of Bulimia Patients Wired Differently 33204 3S BIO Announces Collaboration with Onyx for JAK2 Inhibitors in the North American and European Markets 33200 1S BIO Announces Collaboration with Onyx for JAK2 Inhibitors in the North American and European Markets 33200 2S BIO Announces Collaboration with Onyx for JAK2 Inhibitors in the North American and European Markets 33200 3
...ldwide may soon enjoy new, healthier, tastier appl...etic data which fruit breeders say will help revol...w Zealand,s world renowned fruit science company H...ete the public release of the world,s most extensi...se comprises over 50,000 apple gene sequences - re...
...ers have identified a gene ?and the molecular func...rtant clue to further understanding obesity and ma...lism. , The scientists found that the human prot... "Lipin activity may be an important pharmaceutic...reating conditions that range from obesity to the ...
...uencing of human chromosome 17 and mouse chromosom...the genome of higher mammals, said a Baylor Colleg...effort reported in today,s issue of the journal Na... mouse chromosome has been completely sequenced an...and professor in the BCM department of molecular a...
...atment Botox may have a new use as an adjuvant to ...erapy and radiation treatments, according to a stu...er Research. , The study in mice, led by Bernard ...sité de Louvain in Brussels, Belgium, found that b...ypes of mouse tumors, the tumors, cellular vascula...
Other Biology News:HortResearch science reveals the natural potential of apples 2Rutgers researchers find fat gene 2Mouse to man: The story of chromosomes 2Botox could help target resistant tumors for treatment 2Botox could help target resistant tumors for treatment 3
MAb to Catenin beta, N-terminal (exon 2) Catenin, beta, N-terminal (exon 2)
Anti-Mi-2 Immunogen : Fusion protein corresponding to amino acid residues 474-970 of human Mi-2 Formulation: 0.7M Tris-glycine, pH 7.4, 0.105M NaCl, 0.035% sodium azide, containing 30% glycerol Qual
...egrated system for fluorescent biochip & microarra...lent quality microarray images. The DNAscope V is...n patented confocal laser imaging technology for o.... The DNAscope V images two fluorophores in sequen...
Rabbit polyclonal to Retinoic Acid Receptor beta 2 ( Abpromise for all tested applications). entrezGeneID: 5915
Biology Products: